On March 21 to 22, 2017, the 2017 2017 Asia Pacific Drug Research and Development Leader Summit was solemnly held in Shanghai. Since the development of China's pharmaceutical and biotechnology industries is currently at a critical moment, the global pharmaceutical companies will continue to increase their investment and carry out cooperative innovation in China and Asia in the next five years or even beyond. Against this background, the summit invited global drug research and development leaders, research and development decision-making levels of local drug companies and research and development outsourcing organizations to jointly discuss future Chinese drug research and development innovation and promote innovation and cooperation between China and the Asia-Pacific region. The summit presented many new viewpoints and the latest scientific research progress in the fields of tumor, diabetes and metabolic diseases. It also discussed the mode of pharmaceutical cooperation, risk management methods, outsourcing strategies, data management and so on from a new perspective, with a view to optimizing the research and development costs of pharmaceutical enterprises, improving the research and development efficiency and the competitiveness of pharmaceutical enterprises in Asia and even the world. The agenda of the conference attracted more than 200 research and development leaders and experts from well-known pharmaceutical enterprises at home and abroad to strengthen and optimize the five major topics of cooperation and innovation in Asia-Pacific Drug Research and Development, Opening Innovation and Cooperation Opportunities, New Drug Development and Treatment of diabetes, New Drug Research Topics for type 2 diabetes, and Cooperation and Patent Transfer in China's biomedical research and development.

Dr. Lu, THE president and chief scientific officer of CHIPSCREEN BIOSCIENCES, was invited to attend the meeting and introduced to the participants the next blockbuster new drug of the company after Chidamide, Chiglitazar, which is an original drug for anti-type 2 diabetes. Chiglitazar is a new type of insulin sensitizer candidate drug independently designed, synthesized, screened and developed by CHIPSCREEN BIOSCIENCES. It is also the first original chemical class 1.1 new drug in China to treat type 2 diabetes and a major national drug discovery project. In the treatment of type 2 diabetes, Chiglitazar not only can control blood sugar, but also can treat the disorder of lipid metabolism and abnormal blood pressure usually accompanied by patients, which may be beneficial to the prevention and control of cardiovascular complications, and is expected to become a new and more comprehensive drug treatment method for type 2 diabetes. At present, Chiglitazar has completed phase III clinical trials and entered the group.